

IHCP *bulletin*

INDIANA HEALTH COVERAGE PROGRAMS BT202265 AUGUST 16, 2022

IHCP updates PA criteria for HCPCS code J3399 (Zolgensma)


The Indiana Health Coverage Programs (IHCP) covers onasemnogene abeparvovec-xioi (Zolgensma) for the treatment of spinal muscular atrophy (SMA) with prior authorization (PA) as published in *IHCP Banner Page [BR202007](#)*. Zolgensma is billed using Healthcare Common Procedure Coding System (HCPCS) code J3399 – *Injection, onasemnogene abeparvovec-xioi, per treatment, up to 5x10¹⁵ vector genomes*.

Zolgensma is carved out from managed care benefits, which means that PA requests and claims for J3399, including the specific Zolgensma National Drug Code (NDC), are submitted to Gainwell Technologies and processed through the fee-for-service (FFS) delivery system for all IHCP members as published in *IHCP Banner Page [BR202205](#)*.

PA criteria

PA criteria for Zolgensma have been updated to include members with up to three copies of SMN2. Effective for dates of service on or after Aug. 1, 2022, the following medical necessity criteria must be met:


- Have documentation of genetic testing confirming SMA resulting from bi-allelic mutations in the survival motor neuron 1 (SMN1) gene
- Have no more than **three** copies of SMN2 or displaying clinical symptoms of SMA
- Have documentation demonstrating negative presence of anti-AAV9 antibodies
- Have a gestational age of at least 37 weeks
- Be less than 2 years of age
- Have been prescribed Zolgensma treatment by, or in consultation with, a pediatric neurologist or child neurologist
- Have had no previous Zolgensma treatment
- Have a life expectancy of at least 12 months following treatment
- Have no evidence of advanced SMA, such as one or more of the following:
 - Complete paralysis of limbs
 - Permanent ventilator dependence, defined as:
 - ◆ Requires invasive ventilation (tracheostomy with positive pressure)
 - ◆ Respiratory assistance (including noninvasive ventilator support) for at least 16 hours per day, for at least 14 days (excluding acute, reversible illness or perioperative ventilation)



Note: The prescriber must provide documentation of current clinical status (for example, Brooke Score, six-minute walk test and so on) to compare upon reevaluations of therapy.

For more information

Questions about PA, specific to procedure code J3399 (Zolgensma) for all IHCP-enrolled members, should be directed to Gainwell Technologies at 800-457-4584, option 7. Individual managed care entities (MCEs) establish and publish reimbursement, PA and billing criteria within the managed care delivery system. Questions about managed care billing and PA for services related to but not including procedure code J3399 (Zolgensma) should be directed to the MCE with which the member is enrolled.



QUESTIONS?

If you have questions about this publication, please contact Customer Assistance at 800-457-4584.

TO PRINT

A [printer-friendly version](#) of this publication, in black and white and without photos, is available for your convenience.

COPIES OF THIS PUBLICATION

If you need additional copies of this publication, please download them from the [Bulletins](#) page of the IHCP provider website at in.gov/medicaid/providers.

SIGN UP FOR IHCP EMAIL NOTIFICATIONS

To receive email notices of IHCP publications, subscribe by clicking the blue subscription envelope or sign up from the [IHCP provider website](#) at in.gov/medicaid/providers.

